dgalfano

About dgalfano

This author has not yet filled in any details.
So far dgalfano has created 7 blog entries.

Inflammatory bowel disease

Borniquel S, Jansson EA, Cole MP, Freeman BA, Lundberg JO. 2010. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 48:499-505.

Diabetes, anti-adipogenic and metabolic syndrome

Kelley EE, Baust J, Bonacci G, Golin-Bisello F, Devlin JE, St Croix CM, Watkins SC, Gor S, Cantu-Medellin N, Weidert ER, Frisbee JC, Gladwin MT, Champion HC, Freeman BA, Khoo NK. 2014. Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity. Cardiovasc Res 101(3):352-63.

Cardiac fibrosis and hypertrophy

Villacorta L, Guo Y, Zhang J, Converso-Baran K, Schopfer F, Freeman B, Chen YE. 2015 Electrophilic Nitro-Fatty Acids Exert Cardioprotection against Hypertrophic Remodeling and Fibrosis in Pressure overloaded Mice. FASEB 29 (1) Supplement 640.6.

Pulmonary hypertension and pulmonary fibrosis

Reddy AT, Lakshmi SP, Kleinhenz JM, Sutliff RL, Hart CM, Reddy RC. 2012. Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury. J Immunol 189(11):5411-20.

Kidney failure, chronic kidney injury

Liu S, Jia Z, Zhou L, Liu Y, Ling H, Zhou SF, Zhang A, Du Y, Guan G, Yang T. 2013. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. Am J Physiol Renal Physiol 305(11):F1533-41.

Chemistry and Signaling Pathways

Delmastro-Greenwood M, Freeman BA, Wendell SG. 2014. Redox-Dependent Anti-Inflammatory Signaling Actions of Unsaturated Fatty Acids. Annu. Rev. Physiol. 76:79-105.

Complexa announces Successful Completion of Four Phase 1 Studies of CXA-10 and Planned Phase 2 Initiation in Multiple Orphan Indications during 2016

PITTSBURGH and RADNOR, PA, November 12, 2015 (PRNewswire) -- Complexa Inc., a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammatory diseases, today announced the successful completion of an extensive Phase 1 development program for its lead compound CXA-10.